Van Hulzen Asset Management, LLC Crispr Therapeutics Ag Transaction History
Van Hulzen Asset Management, LLC
- $1.32 Billion
- Q4 2024
A detailed history of Van Hulzen Asset Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Van Hulzen Asset Management, LLC holds 120 shares of CRSP stock, worth $5,218. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120Holding current value
$5,218% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
488Shares Held
60.3MCall Options Held
1.26MPut Options Held
1.81M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$390 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$380 Million0.07% of portfolio
-
State Street Corp Boston, MA2.99MShares$130 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$121 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$119 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.39B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....